IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: A study by the Acute Leukemia French Association

Oncotarget

Volumn 6, Issue 39, 2015, Pages 42345-42353

  Debarri, Houria ^a   Lebon, Delphine ^b   Roumier, Christophe ^a,c   Cheok, Meyling ^c,d   Marceau Renaut, Alice ^a,c   Nibourel, Olivier ^a,c   Geffroy, Sandrine ^a,c   Helevaut, Nathalie ^a   Rousselot, Philippe ^e   Gruson, Bérengère ^b   Gardin, Claude ^f   Chretien, Marie Lorraine ^g   Sebda, Shéhérazade ^d   Figeac, Martin ^d   Berthon, Céline ^a,c   Quesnel, Bruno ^a,c   Boissel, Nicolas ^h   Castaigne, Sylvie ^e   Dombret, Hervé ^h   Renneville, Aline ^a,c   Preudhomme, Claude ^a,c   more..

^a LILLE UNIVERSITY HOSPITAL   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^d Functional Genomic Platform   (France)

^e CENTRE HOSPITALIER DE VERSAILLES   (France)

^f UNIVERSITÉ PARIS 13   (France)

^g DIJON UNIVERSITY HOSPITAL   (France)

^h SAINT LOUIS HOSPITAL   (France)

Author keywords

Acute myeloid leukemia; Minimal residual disease; Next generation sequencing

Indexed keywords

DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; DNA (CYTOSINE 5) METHYLTRANSFERASE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; NUCLEAR PROTEIN; NUCLEOPHOSMIN; TUMOR MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; DNMT3A GENE; GENE LIBRARY; GENE MUTATION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; IDH1 GENE; IDH2 GENE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MOLECULAR EVOLUTION; MUTATION RATE; MYELODYSPLASTIC SYNDROME; NEXT GENERATION SEQUENCING; PATIENT MONITORING; YOUNG ADULT; ACUTE DISEASE; AGED; FRANCE; GENETICS; HIGH THROUGHPUT SEQUENCING; LEUKEMIA, MYELOID; MUTATION; NEOPLASM, RESIDUAL; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

ACUTE DISEASE; ADULT; AGED; BIOMARKERS, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; FRANCE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; NUCLEAR PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84951792911     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5645     Document Type: Article

References (27)

1. Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program 2004:80-97.
2. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18:553-567.
3. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368:2059-2074.
4. Perea G, Lasa A, Aventín A, Domingo A, Villamor N, Queipo de Llano MP, Llorente A, Juncà J, Palacios C, Fernández C, Gallart M, Font L, Tormo M et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia 2006; 20:87-94.
5. Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R, Diverio D, Jones K, Aslett H, Batson E, Rennie K, Angell R, Clark RE et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol OffJ Am Soc Clin Oncol 2009; 27:3650-3658.
6. Krönke J, Schlenk RF, Jensen K-O, Tschürtz F, Corbacioglu A, Gaidzik VI, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol OffJ Am Soc Clin Oncol 2011; 29:2709-2716.
7. Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Lo-Coco F, Arcese W, Amadori S, Venditti A. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012; 119:332-341.
8. Hourigan CS, Karp JE. Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol 2013; 10:460-471.
9. Shayegi N, Kramer M, Bornhäuser M, Schaich M, Schetelig J, Platzbecker U, Röllig C, Heiderich C, Landt O, Ehninger G, Thiede C. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood 2013; 122:83-92.
10. Chou W-C, Peng K-Y, Lei W-C, Ko BS, Tsay W, Kuo CH, Tien HF. Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission. Leukemia 2012; 26:527-529.
11. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, Harris CC, Lichti CF, Townsend RR et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363:2424-2433.
12. Thol F, Damm F, Lüdeking A, Winschel C, Wagner K, Morgan M, Yun H, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Kanz L, Fiedler W et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol OffJ Am Soc Clin Oncol 2011; 29:2889-2896.
13. Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, Cayuela JM, Hayette S, Reman O, Contentin N, Bordessoule D, Pautas C, Botton Sd et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia 2012; 26:1247-1254.
14. Hou H-A, Kuo Y-Y, Liu C-Y, Chou WC, Lee MC, Chen CY, Lin LI, Tseng MH, Huang CF, Chiang YC, Lee FY, Liu MC, Liu CW et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 2012; 119:559-568.
15. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, Straley K, Kernytsky A, Liu W, Gliser C, Yang H, Gross S, Artin E et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013; 340:622-626.
16. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013; 340:626-630.
17. Pirozzi CJ, Reitman ZJ, Yan H. Releasing the Block: Setting Differentiation Free with Mutant IDH Inhibitors. Cancer Cell 2013; 23:570-572.
18. Chaturvedi A, Araujo Cruz MM, Jyotsana N, Sharma A, Yun H, Görlich K, Wichmann M, Schwarzer A, Preller M, Thol F, Meyer J, Haemmerle R, Struys EA et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013; 122:2877-2887.
19. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by wholegenome sequencing. Nature 2012; 481:506-510.
20. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, Kennedy JA, Schimmer AD, Schuh AC, Yee KW, McLeod JL, Doedens M, Medeiros JJ et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506:328-333.
21. Chan SM, Majeti R. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. Int J Hematol 2013; 98:648-657.
22. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, McMichael JF, Schmidt HK, Yellapantula V, Miller CA, Ozenberger BA, Welch JS, Link DC et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014; 20:1472-1478.
23. Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, Chambert K, Mick E, Neale BM, Fromer M, Purcell SM, Svantesson O, Landén M et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371:2477-2487.
24. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N, Chavez A, Higgins JM, Moltchanov V, Kuo FC et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371:2488-2498.
25. Lambert J, Lambert J, Nibourel O, Pautas C, Hayette S, Cayuela JM, Terré C, Rousselot P, Dombret H, Chevret S, Preudhomme C, Castaigne S, Renneville A. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget 2014; 5:6280-6288.
26. Abdelhamid E, Figeac M, Renneville A, Quief S, Villenet C, Boyer T, Nibourel O, Coiteux V, Cassinat B, Lippert E, Helevaut N, Soua Z, Preudhomme C. Quantification of JAK2V617F mutation by next-generation sequencing technology. Am J Hematol 2013; 88:536-537.
27. Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L, Galkin S, Collector MI, Perkins B, Levis MJ, Griffin CA, Sharkis SJ, Borowitz MJ et al. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood 2012; 119:3571-3577.